CoChat
Sign Up
Cited by 73Cancer Cells and MetastasisCellular Mechanics and InteractionsProtease and Inhibitor Mechanisms

The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers

Open access
Kozlova, Nina, Grossman, Joseph E., Iwanicki, Marcin P., Muranen, Taru·2020·Trends in Pharmacological Sciences
DOI 10.1016/j.tips.2020.01.001PMC PMC8812124
Open this paper in CoChat — free account

Abstract

The tumor microenvironment (TME) is a complex neighborhood that consists of immune cells, fibroblasts, pericytes, adipocytes, endothelial and neuronal cells, and the extracellular matrix proteins. TME also consists of physical factors, such as oxygen availability, changing pH, interstitial fluid pressure, and tissue stiffness. As cancer progresses, the physical properties and the cells in the TME change significantly, impacting the efficacy of the therapies and modulating drug resistance. This has led to the development of several new treatments targeting the TME. This review focuses on recent advances on the role of TME in drug resistance, with a particular focus on the ongoing clinical trials aiming at disrupting the TME- and the extracellular matrix-mediated protection against therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tips.2020.01.001

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In TGCTs, the relationship between malignant cells and the surrounding TME plays an important role in disruption of immune balance.

    “In TGCTs, the relationship between malignant cells and the surrounding tumor microenvironment (TME) seems to play an important role in the disruption of this balance [16,17,18,19].”

    From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [17]

    The “Immune cells and the TME” section describes how tumor-cell and stromal signals recruit immunosuppressive cells, supporting the general link between tumor–microenvironment interactions and disrupted immune responses. It does not establish that link specifically in TGCTs; the searches for TGCTs and testicular germ cell tumors found no such discussion in our copy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 107

  1. [3]Halbrook CJ, Pontious C, Kovalenko I, Lapienyte L, Dreyer S, Lee HJ, Thurston G, Zhang Y, Lazarus J, Sajjakulnukit P, Hong HS, Kremer DM, Nelson BS, Kemp S, Zhang L, Chang D, Biankin A, Shi J, Frankel TL, Crawford HC, Morton JP, Pasca di Magliano M, and Lyssiotis CA, Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Cell Metab, 2019. 29(6): p. 1390– 1399 e6. 30827862 PMC6602533
  2. [4]Dalin S, Sullivan MR, Lau AN, Grauman-Boss B, Mueller HS, Kreidl E, Fenoglio S, Luengo A, Lees JA, Vander Heiden MG, Lauffenburger DA, and Hemann MT, Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance. Cancer Res, 2019. PMC7357734 31484670
  3. [5]Mizutani Y, Kobayashi H, Iida T, Asai N, Masamune A, Hara A, Esaki N, Ushida K, Mii S, Shiraki Y, Ando K, Weng L, Ishihara S, Ponik SM, Conklin MW, Haga H, Nagasaka A, Miyata T, Matsuyama M, Kobayashi T, Fujii T, Yamada S, Yamaguchi J, Wang T, Woods SL, Worthley D, Shimamura T, Fujishiro M, Hirooka Y, Takahashi M, and Enomoto A, Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis. Cancer Res, 2019. 31439548
  4. [7]Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, Preall J, and Tuveson DA, IL1-Induced JAK/STAT Signaling Is Antagonized by TGFbeta to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancer Discov, 2019. 9(2): p. 282– 301. 30366930 PMC6368881
  5. [8]Ligorio M, Sil S, Malagon-Lopez J, Nieman LT, Misale S, Di Pilato M, Ebright RY, Karabacak MN, Kulkarni AS, Liu A, Vincent Jordan N, Franses JW, Philipp J, Kreuzer J, Desai N, Arora KS, Rajurkar M, Horwitz E, Neyaz A, Tai E, Magnus NKC, Vo KD, Yashaswini CN, Marangoni F, Boukhali M, Fatherree JP, Damon LJ, Xega K, Desai R, Choz M, Bersani F, Langenbucher A, Thapar V, Morris R, Wellner UF, Schilling O, Lawrence MS, Liss AS, Rivera MN, Deshpande V, Benes CH, Maheswaran S, Haber DA, Fernandez-Del-Castillo C, Ferrone CR, Haas W, Aryee MJ, and Ting DT, Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. Cell, 2019. 178(1): p. 160– 175 e27. 31155233 PMC6697165
  6. [9]Su S, Chen J, Yao H, Liu J, Yu S, Lao L, Wang M, Luo M, Xing Y, Chen F, Huang D, Zhao J, Yang L, Liao D, Su F, Li M, Liu Q, and Song E, CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell, 2018. 172(4): p. 841– 856 e16. 29395328
  7. [10]Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, and Kabos P, Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clin Cancer Res, 2017. 23(7): p. 1710– 1721. 27702820 PMC5378660
  8. [11]Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, and Hunter T, Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature, 2019. 569(7754): p. 131– 135. 30996350 PMC6565370
  9. [12]Plava J, Cihova M, Burikova M, Matuskova M, Kucerova L, and Miklikova S, Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer. Mol Cancer, 2019. 18(1): p. 67. 30927930 PMC6441200
  10. [13]Bohrer LR, Chuntova P, Bade LK, Beadnell TC, Leon RP, Brady NJ, Ryu Y, Goldberg JE, Schmechel SC, Koopmeiners JS, McCarthy JB, and Schwertfeger KL, Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation. Cancer Res, 2014. 74(1): p. 374– 86. 24197137 PMC3933218
  11. [14]Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, and Polyak K, Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res, 2016. 76(22): p. 6495– 6506. 27671678 PMC5344673
  12. [16]Lengyel E, Makowski L, DiGiovanni J, and Kolonin MG, Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors. Trends Cancer, 2018. 4(5): p. 374– 384. 29709261 PMC5932630
  13. [17]Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, Ng MR, Nia HT, Grahovac J, Kao S, Babykutty S, Huang Y, Jung K, Rahbari NN, Han X, Chauhan VP, Martin JD, Kahn J, Huang P, Desphande V, Michaelson J, Michelakos TP, Ferrone CR, Soares R, Boucher Y, Fukumura D, and Jain RK, Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. Cancer Discov, 2016. 6(8): p. 852– 69. 27246539 PMC4972679
  14. [18]Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, Stevens B, Pei S, Balys M, Ashton JM, Klemm DJ, Woolthuis CM, Stranahan AW, Park CY, and Jordan CT, Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. Cell Stem Cell, 2016. 19(1): p. 23– 37. 27374788 PMC4938766
  15. [19]Duong MN, Cleret A, Matera EL, Chettab K, Mathe D, Valsesia-Wittmann S, Clemenceau B, and Dumontet C, Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. Breast Cancer Res, 2015. 17: p. 57. 25908175 PMC4482271
  16. [20]Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, and Lengyel E, Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med, 2011. 17(11): p. 1498– 503. 22037646 PMC4157349
  17. [21]Balaban S, Shearer RF, Lee LS, van Geldermalsen M, Schreuder M, Shtein HC, Cairns R, Thomas KC, Fazakerley DJ, Grewal T, Holst J, Saunders DN, and Hoy AJ, Adipocyte lipolysis links obesity to breast cancer growth: adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer Metab, 2017. 5: p. 1. 28101337 PMC5237166
  18. [22]Zhang M, Di Martino JS, Bowman RL, Campbell NR, Baksh SC, Simon-Vermot T, Kim IS, Haldeman P, Mondal C, Yong-Gonzales V, Abu-Akeel M, Merghoub T, Jones DR, Zhu XG, Arora A, Ariyan CE, Birsoy K, Wolchok JD, Panageas KS, Hollmann T, Bravo-Cordero JJ, and White RM, Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. Cancer Discov, 2018. 8(8): p. 1006– 1025. 29903879 PMC6192670
  19. [23]Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, Huang Y, Rahbari NN, Roberge S, Wang D, Gomes-Santos IL, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Tolaney SM, Krop IE, Duda DG, Boucher Y, Fukumura D, and Jain RK, Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci Transl Med, 2018. 10(432). PMC5936748 29540614
  20. [24]Munn LL and Jain RK, Vascular regulation of antitumor immunity. Science, 2019. 365(6453): p. 544– 545. 31395771 PMC7321824
  21. [25]van Dijk CG, Nieuweboer FE, Pei JY, Xu YJ, Burgisser P, van Mulligen E, el Azzouzi H, Duncker DJ, Verhaar MC, and Cheng C, The complex mural cell: pericyte function in health and disease. Int J Cardiol, 2015. 190: p. 75– 89. 25918055
  22. [26]Zhou W, Chen C, Shi Y, Wu Q, Gimple RC, Fang X, Huang Z, Zhai K, Ke SQ, Ping YF, Feng H, Rich JN, Yu JS, Bao S, and Bian XW, Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy. Cell Stem Cell, 2017. 21(5): p. 591– 603 e4. 29100012 PMC5687837
  23. [28]Mauffrey P, Tchitchek N, Barroca V, Bemelmans A, Firlej V, Allory Y, Romeo PH, and Magnon C, Progenitors from the central nervous system drive neurogenesis in cancer. Nature, 2019. 569(7758): p. 672– 678. 31092925
  24. [29]Chen SH, Zhang BY, Zhou B, Zhu CZ, Sun LQ, and Feng YJ, Perineural invasion of cancer: a complex crosstalk between cells and molecules in the perineural niche. Am J Cancer Res, 2019. 9(1): p. 1– 21. 30755808 PMC6356921
  25. [30]Datta M, Coussens LM, Nishikawa H, Hodi FS, and Jain RK, Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. Am Soc Clin Oncol Educ Book, 2019. 39: p. 165– 174. 31099649 PMC6596289
  26. [32]Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Senbabaoglu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Hoglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, and Powles T, TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature, 2018. 554(7693): p. 544– 548. 29443960 PMC6028240
  27. [33]Kuang DM, Wu Y, Chen N, Cheng J, Zhuang SM, and Zheng L, Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood, 2007. 110(2): p. 587– 95. 17395778
  28. [34]McWhorter FY, Davis CT, and Liu WF, Physical and mechanical regulation of macrophage phenotype and function. Cell Mol Life Sci, 2015. 72(7): p. 1303– 16. 25504084 PMC4795453
  29. [35]Liguori M, Solinas G, Germano G, Mantovani A, and Allavena P, Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma. Cancers (Basel), 2011. 3(4): p. 3740– 61. 24213109 PMC3763394
  30. [36]Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, and Ruttinger D, Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer, 2017. 5(1): p. 53. 28716061 PMC5514481
  31. [37]Ruffell B and Coussens LM, Macrophages and therapeutic resistance in cancer. Cancer Cell, 2015. 27(4): p. 462– 72. 25858805 PMC4400235
  32. [38]Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, and Duda DG, CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology, 2015. 61(5): p. 1591– 602. 25529917 PMC4406806
  33. [39]Dvorak HF, Tumors: wounds that do not heal-redux. Cancer Immunol Res, 2015. 3(1): p. 1– 11. 25568067 PMC4288010
  34. [41]Vennin C, Melenec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, Herrmann D, Reed DA, Lucas MC, Warren SC, Elgundi Z, Pinese M, Kalna G, Roden D, Samuel M, Zaratzian A, Grey ST, Da Silva A, Leung W, Australian Pancreatic Genome I, Mathivanan S, Wang Y, Braithwaite AW, Christ D, Benda A, Parkin A, Phillips PA, Whitelock JM, Gill AJ, Sansom OJ, Croucher DR, Parker BL, Pajic M, Morton JP, Cox TR, and Timpson P, CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nat Commun, 2019. 10(1): p. 3637. 31406163 PMC6691013
  35. [42]Sampayo RG, Toscani AM, Rubashkin MG, Thi K, Masullo LA, Violi IL, Lakins JN, Caceres A, Hines WC, Coluccio Leskow F, Stefani FD, Chialvo DR, Bissell MJ, Weaver VM, and Simian M, Fibronectin rescues estrogen receptor alpha from lysosomal degradation in breast cancer cells. J Cell Biol, 2018. 217(8): p. 2777– 2798. 29980625 PMC6080927
  36. [43]Amrutkar M, Aasrum M, Verbeke CS, and Gladhaug IP, Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells. BMC Cancer, 2019. 19(1): p. 596. 31208372 PMC6580453
  37. [44]Kaur A, Ecker BL, Douglass SM, Kugel CH 3rd, Webster MR, Almeida FV, Somasundaram R, Hayden J, Ban E, Ahmadzadeh H, Franco-Barraza J, Shah N, Mellis IA, Keeney F, Kossenkov A, Tang HY, Yin X, Liu Q, Xu X, Fane M, Brafford P, Herlyn M, Speicher DW, Wargo JA, Tetzlaff MT, Haydu LE, Raj A, Shenoy V, Cukierman E, and Weeraratna AT, Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discov, 2019. 9(1): p. 64– 81. 30279173 PMC6328333
  38. [45]Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB, and Brugge JS, Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell, 2012. 21(2): p. 227– 39. 22340595 PMC3297962
  39. [46]Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sanchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, and Arteaga CL, Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2(+) Breast Cancer. Cancer Res, 2017. 77(12): p. 3280– 3292. 28396358 PMC5482178
  40. [47]Dangi-Garimella S, Krantz SB, Barron MR, Shields MA, Heiferman MJ, Grippo PJ, Bentrem DJ, and Munshi HG, Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res, 2011. 71(3): p. 1019– 28. 21148071 PMC3076124
  41. [48]Rainero E, Howe JD, Caswell PT, Jamieson NB, Anderson K, Critchley DR, Machesky L, and Norman JC, Ligand-Occupied Integrin Internalization Links Nutrient Signaling to Invasive Migration. Cell Rep, 2015. 10(3): p. 398– 413. 25600874
  42. [49]Muranen T, Iwanicki MP, Curry NL, Hwang J, DuBois CD, Coloff JL, Hitchcock DS, Clish CB, Brugge JS, and Kalaany NY, Starved epithelial cells uptake extracellular matrix for survival. Nat Commun, 2017. 8: p. 13989. 28071763 PMC5234072
  43. [52]Olivares O, Mayers JR, Gouirand V, Torrence ME, Gicquel T, Borge L, Lac S, Roques J, Lavaut MN, Berthezene P, Rubis M, Secq V, Garcia S, Moutardier V, Lombardo D, Iovanna JL, Tomasini R, Guillaumond F, Vander Heiden MG, and Vasseur S, Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat Commun, 2017. 8: p. 16031. 28685754 PMC5504351
  44. [53]Tian C, Clauser KR, Ohlund D, Rickelt S, Huang Y, Gupta M, Mani DR, Carr SA, Tuveson DA, and Hynes RO, Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc Natl Acad Sci U S A, 2019. 116(39): p. 19609– 19618. 31484774 PMC6765243
  45. [54]Han L, Lam EW, and Sun Y, Extracellular vesicles in the tumor microenvironment: old stories, but new tales. Mol Cancer, 2019. 18(1): p. 59. 30925927 PMC6441234
  46. [55]Namee NM and O’Driscoll L, Extracellular vesicles and anti-cancer drug resistance. Biochim Biophys Acta Rev Cancer, 2018. 1870(2): p. 123– 136. 30003999
  47. [56]Trichet L, Le Digabel J, Hawkins RJ, Vedula SR, Gupta M, Ribrault C, Hersen P, Voituriez R, and Ladoux B, Evidence of a large-scale mechanosensing mechanism for cellular adaptation to substrate stiffness. Proc Natl Acad Sci U S A, 2012. 109(18): p. 6933– 8. 22509005 PMC3344951
  48. [57]Li Y, Fanous MJ, Kilian KA, and Popescu G, Quantitative phase imaging reveals matrix stiffness-dependent growth and migration of cancer cells. Sci Rep, 2019. 9(1): p. 248. 30670739 PMC6343033
  49. [58]Oudin MJ and Weaver VM, Physical and Chemical Gradients in the Tumor Microenvironment Regulate Tumor Cell Invasion, Migration, and Metastasis. Cold Spring Harb Symp Quant Biol, 2016. 81: p. 189– 205. 28424337
  50. [59]Li X and Thompson CB, Targeting hyaluronan accumulation in the tumor microenvironment. Oncotarget, 2018. 9(100): p. 37349– 37351. 30647836 PMC6324773
  51. [60]Petrova V, Annicchiarico-Petruzzelli M, Melino G, and Amelio I, The hypoxic tumour microenvironment. Oncogenesis, 2018. 7(1): p. 10. 29362402 PMC5833859
  52. [61]Myllyharju J and Schipani E, Extracellular matrix genes as hypoxia-inducible targets. Cell Tissue Res, 2010. 339(1): p. 19– 29. 19662436 PMC3074490
  53. [62]Labrousse-Arias D, Martinez-Ruiz A, and Calzada MJ, Hypoxia and Redox Signaling on Extracellular Matrix Remodeling: From Mechanisms to Pathological Implications. Antioxid Redox Signal, 2017. 27(12): p. 802– 822. 28715969
  54. [63]Gilkes DM, Bajpai S, Chaturvedi P, Wirtz D, and Semenza GL, Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J Biol Chem, 2013. 288(15): p. 10819– 29. 23423382 PMC3624462
  55. [65]Kietzmann T, Samoylenko A, Roth U, and Jungermann K, Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Blood, 2003. 101(3): p. 907– 14. 12393531
  56. [67]Raab-Westphal S, Marshall JF, and Goodman SL, Integrins as Therapeutic Targets: Successes and Cancers. Cancers (Basel), 2017. 9(9). PMC5615325 28832494
  57. [68]Cooper J and Giancotti FG, Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell, 2019. 35(3): p. 347– 367. 30889378 PMC6684107
  58. [70]Carlson P, Dasgupta A, Grzelak CA, Kim J, Barrett A, Coleman IM, Shor RE, Goddard ET, Dai J, Schweitzer EM, Lim AR, Crist SB, Cheresh DA, Nelson PS, Hansen KC, and Ghajar CM, Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. Nat Cell Biol, 2019. 21(2): p. 238– 250. 30664790 PMC6948102
  59. [71]Kleinschmidt EG and Schlaepfer DD, Focal adhesion kinase signaling in unexpected places. Curr Opin Cell Biol, 2017. 45: p. 24– 30. 28213315 PMC5482783
  60. [73]Tavora B, Reynolds LE, Batista S, Demircioglu F, Fernandez I, Lechertier T, Lees DM, Wong PP, Alexopoulou A, Elia G, Clear A, Ledoux A, Hunter J, Perkins N, Gribben JG, and Hodivala-Dilke KM, Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Nature, 2014. 514(7520): p. 112– 6. 25079333 PMC4533916
  61. [74]Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, Pachter JA, Wang-Gillam A, and DeNardo DG, Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med, 2016. 22(8): p. 851– 60. 27376576 PMC4935930
  62. [75]Patel A, Sabbineni H, Clarke A, and Somanath PR, Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis. Life Sci, 2016. 157: p. 52– 61. 27245276 PMC4956571
  63. [76]Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, and Dibb NJ, Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia, 2009. 23(3): p. 590– 4. 18784745
  64. [77]Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, and Lyons AB, Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood, 2005. 105(8): p. 3127– 32. 15637141
  65. [78]Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, and Massague J, Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell, 2009. 16(1): p. 67– 78. 19573813 PMC2749247
  66. [79]Martin JD, Seano G, and Jain RK, Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges. Annu Rev Physiol, 2019. 81: p. 505– 534. 30742782 PMC6571025
  67. [80]Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, and Ruttinger D, Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell, 2014. 25(6): p. 846– 59. 24898549
  68. [81]Salvagno C, Ciampricotti M, Tuit S, Hau CS, van Weverwijk A, Coffelt SB, Kersten K, Vrijland K, Kos K, Ulas T, Song JY, Ooi CH, Ruttinger D, Cassier PA, Jonkers J, Schultze JL, Ries CH, and de Visser KE, Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nat Cell Biol, 2019. 21(4): p. 511– 521. 30886344 PMC6451630
  69. [82]Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, Hashimoto A, Vonteddu P, Behera R, Goins MA, Mulligan C, Nam B, Hockstein N, Denstman F, Shakamuri S, Speicher DW, Weeraratna AT, Chao T, Vonderheide RH, Languino LR, Ordentlich P, Liu Q, Xu X, Lo A, Pure E, Zhang C, Loboda A, Sepulveda MA, Snyder LA, and Gabrilovich DI, Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Cancer Cell, 2017. 32(5): p. 654– 668 e5. 29136508 PMC5827952
  70. [83]Chen IX, Chauhan VP, Posada J, Ng MR, Wu MW, Adstamongkonkul P, Huang P, Lindeman N, Langer R, and Jain RK, Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc Natl Acad Sci U S A, 2019. PMC6410779 30700545
  71. [84]Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing D, Kowalski M, Mingari MC, Vianello F, Birrer M, Orsulic S, Dranoff G, and Poznansky MC, CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res, 2011. 71(16): p. 5522– 5534. 21742774 PMC3959864
  72. [85]Momin N, Mehta NK, Bennett NR, Ma L, Palmeri JR, Chinn MM, Lutz EA, Kang B, Irvine DJ, Spranger S, and Wittrup KD, Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Sci Transl Med, 2019. 11(498). PMC7811803 31243150
  73. [86]Alaseem A, Alhazzani K, Dondapati P, Alobid S, Bishayee A, and Rathinavelu A, Matrix Metalloproteinases: A challenging paradigm of cancer management. Semin Cancer Biol, 2019. 56: p. 100– 115. 29155240
  74. [87]Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T, Drebin JA, O’Dwyer PJ, Liddle C, Tuveson DA, Downes M, and Evans RM, Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell, 2014. 159(1): p. 80– 93. 25259922 PMC4177038
  75. [88]Ferrer-Mayorga G, Gomez-Lopez G, Barbachano A, Fernandez-Barral A, Pena C, Pisano DG, Cantero R, Rojo F, Munoz A, and Larriba MJ, Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer. Gut, 2017. 66(8): p. 1449– 1462. 27053631 PMC5530491
  76. [89]Kong F, Li L, Wang G, Deng X, Li Z, and Kong X, VDR signaling inhibits cancer-associated-fibroblasts’ release of exosomal miR-10a-5p and limits their supportive effects on pancreatic cancer cells. Gut, 2019. 68(5): p. 950– 951. 29695492
  77. [90]Wu X, Hu W, Lu L, Zhao Y, Zhou Y, Xiao Z, Zhang L, Zhang H, Li X, Li W, Wang S, Cho CH, Shen J, and Li M, Repurposing vitamin D for treatment of human malignancies via targeting tumor microenvironment. Acta Pharm Sin B, 2019. 9(2): p. 203– 219. 30972274 PMC6437556
  78. [91]Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Gordon D, Copeland T, D’Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, and Group VR, Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med, 2019. 380(1): p. 33– 44. 30415629 PMC6425757
  79. [92]Bhattacharjee V, Zhou Y, and Yen TJ, A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. Cell Cycle, 2014. 13(24): p. 3839– 56. 25558828 PMC4615005
  80. [93]Jeon SM and Shin EA, Exploring vitamin D metabolism and function in cancer. Exp Mol Med, 2018. 50(4): p. 20. PMC5938036 29657326
  81. [94]Stylianopoulos T, Munn LL, and Jain RK, Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside. Trends Cancer, 2018. 4(4): p. 292– 319. 29606314 PMC5930008
  82. [95]Thompson CB, Shepard HM, O’Connor PM, Kadhim S, Jiang P, Osgood RJ, Bookbinder LH, Li X, Sugarman BJ, Connor RJ, Nadjsombati S, and Frost GI, Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther, 2010. 9(11): p. 3052– 64. 20978165
  83. [96]Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, and Hingorani SR, Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell, 2012. 21(3): p. 418– 29. 22439937 PMC3371414
  84. [97]Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, and Tuveson DA, Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut, 2013. 62(1): p. 112– 20. 22466618 PMC3551211
  85. [98]Li X, Shepard HM, Cowell JA, Zhao C, Osgood RJ, Rosengren S, Blouw B, Garrovillo SA, Pagel MD, Whatcott CJ, Han H, Von Hoff DD, Taverna DM, LaBarre MJ, Maneval DC, and Thompson CB, Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression. Clin Cancer Res, 2018. 24(19): p. 4798– 4807. 30084839 PMC6743334
  86. [99]Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, and Hendifar AE, HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. J Clin Oncol, 2018. 36(4): p. 359– 366. 29232172
  87. [100]Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, Thumar J, Chiorean EG, Shields AF, Behl D, Mehan PT, Gaur R, Seery T, Guthrie KA, and Hochster HS, Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. J Clin Oncol, 2019. 37(13): p. 1062– 1069. 30817250 PMC6494359
  88. [101]Sullivan WJ, Mullen PJ, Schmid EW, Flores A, Momcilovic M, Sharpley MS, Jelinek D, Whiteley AE, Maxwell MB, Wilde BR, Banerjee U, Coller HA, Shackelford DB, Braas D, Ayer DE, de Aguiar Vallim TQ, Lowry WE, and Christofk HR, Extracellular Matrix Remodeling Regulates Glucose Metabolism through TXNIP Destabilization. Cell, 2018. 175(1): p. 117– 132 e21. 30197082 PMC6151140
  89. [102]Curran CS and Keely PJ, Breast tumor and stromal cell responses to TGF-beta and hypoxia in matrix deposition. Matrix Biol, 2013. 32(2): p. 95– 105. 23262216 PMC3615133
  90. [103]Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, and Sheppard D, The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell, 1999. 96(3): p. 319– 28. 10025398
  91. [104]de Gramont A, Faivre S, and Raymond E, Novel TGF-beta inhibitors ready for prime time in onco-immunology. Oncoimmunology, 2017. 6(1): p. e1257453. 28197376 PMC5283641
  92. [105]Burstein SH, Ajulemic acid: potential treatment for chronic inflammation. Pharmacol Res Perspect, 2018. 6(2): p. e00394. 29638269 PMC5891661
  93. [106]Elahi-Gedwillo KY, Carlson M, Zettervall J, and Provenzano PP, Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma. Cancer Res, 2019. 79(2): p. 372– 386. 30401713 PMC6335156
  94. [107]Takai K, Le A, Weaver VM, and Werb Z, Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget, 2016. 7(50): p. 82889– 82901. 27756881 PMC5341254
  95. [108]Coulson R, Liew SH, Connelly AA, Yee NS, Deb S, Kumar B, Vargas AC, O’Toole SA, Parslow AC, Poh A, Putoczki T, Morrow RJ, Alorro M, Lazarus KA, Yeap EFW, Walton KL, Harrison CA, Hannan NJ, George AJ, Clyne CD, Ernst M, Allen AM, and Chand AL, The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget, 2017. 8(12): p. 18640– 18656. 28416734 PMC5386636
  96. [110]Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, Stylianopoulos T, Mousa AS, Han X, Adstamongkonkul P, Popovic Z, Huang P, Bawendi MG, Boucher Y, and Jain RK, Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun, 2013. 4: p. 2516. 24084631 PMC3806395
  97. [111]Busby J, McMenamin U, Spence A, Johnston BT, Hughes C, and Cardwell CR, Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study. Aliment Pharmacol Ther, 2018. 47(2): p. 279– 288. 29105106
  98. [112]Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernandez-Del Castillo C, and Hong TS, Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol, 2019. 5(7): p. 1020– 1027. 31145418 PMC6547247
  99. [113]Zhao Y, Cao J, Melamed A, Worley M, Gockley A, Jones D, Nia HT, Zhang Y, Stylianopoulos T, Kumar AS, Mpekris F, Datta M, Sun Y, Wu L, Gao X, Yeku O, Del Carmen MG, Spriggs DR, Jain RK, and Xu L, Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proc Natl Acad Sci U S A, 2019. 116(6): p. 2210– 2219. 30659155 PMC6369817
  100. [114]Weigelt B, Ghajar CM, and Bissell MJ, The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Adv Drug Deliv Rev, 2014. 69–70: p. 42– 51. PMC4186247 24412474
  101. [115]Serebriiskii I, Castello-Cros R, Lamb A, Golemis EA, and Cukierman E, Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix Biol, 2008. 27(6): p. 573– 585. 18411046 PMC2603546
  102. [116]Langhans SA, Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning. Front Pharmacol, 2018. 9: p. 6. 29410625 PMC5787088
  103. [117]Schedin P and Keely PJ, Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression. Cold Spring Harb Perspect Biol, 2011. 3(1): p. a003228. 20980442 PMC3003460
  104. [118]Boyd NF, Lockwood GA, Byng JW, Tritchler DL, and Yaffe MJ, Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev, 1998. 7(12): p. 1133– 44. 9865433
  105. [119]Conklin MW, Eickhoff JC, Riching KM, Pehlke CA, Eliceiri KW, Provenzano PP, Friedl A, and Keely PJ, Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol, 2011. 178(3): p. 1221– 32. 21356373 PMC3070581
  106. [120]Brighton HE, Angus SP, Bo T, Roques J, Tagliatela AC, Darr DB, Karagoz K, Sciaky N, Gatza ML, Sharpless NE, Johnson GL, and Bear JE, New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging. Cancer Res, 2018. 78(2): p. 542– 557. 29180473 PMC6132242
  107. [121]Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, Larkin J, Marais R, and Sahai E, Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling. Cancer Cell, 2015. 27(4): p. 574– 88. 25873177 PMC4402404

Cited by

Sorted by citations

Authors
Kozlova, N., Grossman, J. E., Iwanicki, M. P., & Muranen, T.
Affiliations
  • Beth Israel Deaconess Medical Center (US)
  • Stevens Institute of Technology (US)
Corresponding author
Muranen, Taru
ORCID
Venue
Trends in Pharmacological Sciences
Publisher
Elsevier BV
Published
2020-03
Volume
41
Issue
3
Pages
183-198
ISSN
0165-6147 (ISSN-L)
DOI
10.1016/j.tips.2020.01.001
PMC
PMC8812124
OpenAlex
W3003803008
Cited by
73
References
14
Citations by year
2026: 8 · 2025: 18 · 2024: 8 · 2023: 10 · 2022: 7 · 2021: 16 · 2020: 6
FWCI
1.06
Type
journal article
Language
en
Open access
Licence
Locations
  • Trends in Pharmacological Sciences (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Susan G. Komen (18547665)
  • National Cancer Institute
  • American Cancer Society (#RSG-19-0201-CSM)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
Keywords
tumor microenvironment, extracellular matrix, cancer-associated fibroblasts, stromal cells, drug resistance, TME-targeted therapy, clinical trials, tissue stiffness, interstitial fluid pressure, tumor hypoxia, interstitial pH
MeSH terms
Pharmaceutical Preparations, Extracellular Matrix, Humans, Neoplasms, Stromal Cells, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review